These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18027154)

  • 1. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
    Papageorgio C; Perry MC
    Cancer Invest; 2007 Oct; 25(7):647-57. PubMed ID: 18027154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.
    Khan MH; Alam M; Yoo S
    Dermatol Surg; 2011 Sep; 37(9):1199-209. PubMed ID: 21615602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
    Xiong HQ; Abbruzzese JL
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):31-7. PubMed ID: 12422311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR as a target: rationale for therapy.
    Wujcik D
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
    Chang BW; Saif MW
    JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR signaling and drug discovery.
    Lurje G; Lenz HJ
    Oncology; 2009; 77(6):400-10. PubMed ID: 20130423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD
    Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
    Ayyappan S; Prabhakar D; Sharma N
    Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
    Philip PA; Lutz MP
    Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Researchers optimistic about targeted drugs for pancreatic cancer.
    McBride G
    J Natl Cancer Inst; 2004 Nov; 96(21):1570-2. PubMed ID: 15523082
    [No Abstract]   [Full Text] [Related]  

  • 17. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.
    Scartozzi M; Pierantoni C; Berardi R; Antognoli S; Bearzi I; Cascinu S
    Anal Quant Cytol Histol; 2006 Apr; 28(2):61-8. PubMed ID: 16637508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer.
    Hong L; Han Y; Brain L
    Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):111-7. PubMed ID: 24410474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of novel targeted therapies in the clinic.
    Herbst RS
    Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S21-7. PubMed ID: 15928655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.